RETRACTED: Evaluation of the safety and efficacy of bremelanotide, a melanocortin receptor agonist, in female subjects with arousal disorder: a double-blind placebo-controlled, fixed dose, randomized study.
Safarinejad. Mohammad Reza MR
Key Findings
- Paper retracted due to serious methodological and data concerns
- Original data not provided by authors
- No validated safety or efficacy information available
Practical Outcomes
- Because the article is retracted, there’s nothing actionable to take from it. Skip this source when planning pt‑141 protocols.
Summary
The study on bremelanotide (pt‑141) was withdrawn, so its results can’t be trusted and there’s no reliable info for use.
Abstract
This article has been retracted: please see Elsevier Policy on Article Withdrawal (https://www.elsevier.com/about/our-business/policies/article-withdrawal). This article has been retracted at the request of the Editor-in-Chief. Following the retraction of Dr. Safarinejad's work by other journals, The Journal of Sexual Medicine has undertaken an extensive re-review of all papers Dr. Safarinejad published with the journal. Following an intensive re-evaluation and close scrutiny of the manuscripts, our expert reviewers raised multiple concerning questions about the methodology, results, and statistical interpretation as presented in this article. Dr. Safarinejad was contacted to provide his original data and offer explanations to address the concerns expressed by the reviewers. Dr Safarinejad chose not to respond. Consequently, we can no longer verify the results or methods as presented and therefore retract the article.
Study Information
pubmed
2007
2007-12-28T00:00:00.000Z
10.1111/j.1743-6109.2007.00698.x
66
35